Silence Therapeutics PLC Silence Therapeutics to Participate in Conferences (5527T)

TIDMSLN

RNS Number : 5527T

Silence Therapeutics PLC

21 July 2020

Silence Therapeutics to Participate in US Virtual Investor Conferences in August

21 July 2020

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Company management will be participating in three virtual conferences, details of which can be found below:

William Blair Biotech Focus Conference

 
 
Date:     Thursday, August 6, 2020 
Time:     2:00 pm EDT (19:00 BST) 
Panel:    30 Years of RNA-Targeted Therapies - Where Are 
           We Now 
 

BTIG Virtual Biotechnology Conference

 
 
Date:            Monday, August 10, 2020 
Time:            9:30 am EDT (14:30 BST) 
Webcast link:    Silence Therapeutics fireside chat 
 

Canaccord 40(th) Annual Growth Conference

 
 
Date:            Thursday, August 13, 2020 
Time:            11:30 am EDT (16:30 BST) 
Webcast link:    Silence Therapeutics presentation 
 

Live webcasts of the BTIG Virtual Biotechnology Conference and the Canaccord Growth Conference can be accessed via the Investors section of the Company's website at www.silence-therapeutics.com . An archived replay of the webcasts will be available for 60 days on the Company's website after the conference.

For more information, please contact:

 
 Silence Therapeutics plc                     Tel: [phone] 
  Iain Ross, Executive Chairman                6900 
  Rob Quinn, Chief Financial Officer 
 Investec (Nominated Adviser and Broker)      Tel: +44 (0) 20 
  Daniel Adams/Gary Clarence                   7597 5970 
 European IR                                  Tel: +44 (0) 20 
  Consilium Strategic Communications           3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  [e-mail] 
 U.S. IR                                       Tel: [phone] 
  Westwicke 
  Peter Vozzo 
  [e-mail] 
 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCRMMBTMTJTTFM

(END) Dow Jones Newswires

July 21, 2020 02:00 ET (06:00 GMT)